Imagine a world where childhood leukemia is no longer a death sentence. That's the bold vision driving a groundbreaking research initiative at the University of Barcelona, thanks to a significant boost from the Association Against Cancer (AECC). But here's where it gets even more inspiring: this isn't just about funding—it's about transforming lives and pushing the boundaries of what's possible in cancer treatment.
Professor Óscar Molina, a leading figure in the Department of Physiological Sciences at the Faculty of Medicine and Health Sciences, has been awarded a prestigious LAB AECC 2025 grant of €372,500. His mission? To uncover the Achilles' heel of childhood leukemia with aneuploidies—a condition where cancer cells thrive despite having an abnormal number of chromosomes. And this is the part most people miss: by understanding how these cells survive, Molina aims to design treatments that specifically target and weaken them, potentially increasing survival rates and reducing side effects in young patients.
This grant is part of a larger €13.11 million investment by the AECC, which has awarded 54 research grants and accredited six research centers in the Barcelona province. The initiative covers all stages of research, from foundational studies to clinical trials, with a bold goal: achieving a 70% cancer survival rate by 2030. Controversially, some critics argue that such ambitious targets may raise unrealistic expectations, but supporters believe they are essential to drive innovation.
At the grant ceremony on February 27, Núria Montserrat Pulido, Catalonia’s Minister for Research and Universities, emphasized the power of collaboration between institutions, scientists, and social entities. Her words underscored the collective effort needed to turn research into real-world solutions for cancer patients.
Adding to the momentum, Filotea Crasovan, a student at the Faculty of Medicine and Health Sciences, has received a grant under the AECC’s laboratory internship program, highlighting the organization’s commitment to nurturing the next generation of researchers.
Nationally, the AECC stands out as the largest private funder of cancer research, with €157 million invested in 792 ongoing projects involving over 3,000 researchers across 160 centers in 38 provinces. In 2025 alone, the association awarded €40 million through 282 new grants, cementing its role as a leader in the fight against cancer.
But here’s a thought-provoking question: With such significant investments, how can we ensure that breakthroughs in the lab translate into accessible treatments for all patients, regardless of their location or socioeconomic status?
Professor Molina’s project not only promises to advance our understanding of childhood leukemia but also allows him to establish his own laboratory, solidifying his scientific career. This dual impact—progress in research and the development of future leaders—is a testament to the AECC’s holistic approach.
To learn more about Professor Molina’s work, watch his interview here: https://web.ub.edu/documents/d/actualitat/oscar-molina_video-mp4.
Disclaimer: This material is a public release from the originating organization and may reflect a specific point in time. It has been edited for clarity, style, and length. Mirage.News does not take institutional positions or sides, and all views expressed are solely those of the author(s). View the full article here: https://www.miragenews.com/cancer-association-boosts-research-at-barcelona-1628151/.
